VERU INC. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Veru Inc. enrolled 239 patients (exceeding 200-patient target) in its Phase 2b PLATEAU trial testing enobosarm + semaglutide for quality weight loss in older obese patients. The company secured a clinical supply agreement with Novo Nordisk (announced June 2026) and received USPTO Notice of Allowance for a patent covering enobosarm-GLP1 combinations, expiring October 2044. Interim results expected Q1 2027; final data Q4 2027. YTD net loss improved to $15.1M ($0.68/share) vs. $24.2M ($1.65/share) prior year; cash position increased to $23.9M from $15.8M.
Why this rating
Full enrollment + Novo partnership + patent allowance are material near-term milestones for 64M-cap biotech. Interim data in ~6 months is key catalyst. Cash runway adequate but dependent on successful trial outcomes.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.